ImmunoGen, Inc.

Grace Liu from Sino Biological discusses Antibody-Drug Conjugates (ADCs), a cancer therapy combining precision targeting with potent cytotoxic drugs. ADCs consist of a monoclonal antibody, cytotoxic payload, and linker, balancing efficacy and safety. Sino Biological offers comprehensive ADC development solutions, aiding in the complex process from discovery to clinical studies.

Crinetics Pharmaceuticals appoints Isabel Kalofonos as Chief Commercial Officer to lead commercial strategy for paltusotine, a potential treatment for acromegaly, and pre-commercialization activities for the company's pipeline.

FDA grants Merck's sacituzumab tirumotecan (sac-TMT) breakthrough therapy designation for advanced non-squamous NSCLC with EGFR mutations, post-chemotherapy progression. This marks the first BTD for sac-TMT, an ADC developed with Kelun-Biotech, with Merck holding global marketing rights except in Greater China.

The global antibody drug conjugate market is projected to grow from USD 7.72 billion to USD 23.3 billion by 2035, driven by advancements in antibody engineering and clinical trial successes. Over 280 ADCs are approved or in clinical studies, with 250+ in early development. Key segments include breast cancer, solid tumors, and HER-2 antigen. North America leads in market share, while Asia-Pacific shows higher growth potential.

AbbVie's Elahere (mirvetuximab soravtansine) receives European Commission approval for treating platinum-resistant ovarian cancer, becoming the first FRα-directed ADC in the EU for this indication. The approval is based on the MIRASOL study, showing Elahere reduced tumor progression risk by 35% and improved overall survival.

AbbVie's $10.1 billion acquisition of ImmunoGen secures EU approval for Elahere, the first drug for FRα-positive, platinum-resistant ovarian cancer. Elahere, an ADC, was approved in the US in 2022 and received full FDA approval in March. The EU approval ends a 10-year treatment hiatus and shows improved overall survival compared to chemotherapy. The MIRASOL trial supports these findings, with a 33% reduction in death risk and 35% improvement in progression-free survival. Rivals include Eisai's farletuzumab ecteribulin, but Elahere is expected to dominate, with potential sales of $2.8 billion by 2029.

The European Commission has approved AbbVie’s Elahere for treating FRα-positive, platinum-resistant ovarian cancer, offering a 35% reduction in disease progression risk compared to standard chemotherapy. This marks the first new treatment in a decade for this condition in the EU, with potential revenue of $1.98bn by 2030.

AbbVie's stock dropped 13% after emraclidine, a schizophrenia drug from its $8.7 billion Cerevel Therapeutics acquisition, failed in phase 2 trials. The failure benefits Bristol-Myers Squibb, whose Cobenfy received FDA approval in September, and Neurocrine Biosciences, which had a successful phase 2 trial for its M4 agonist.

Antibody drug conjugates (ADCs) are a transformative class in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is expected to surpass $50B by 2030, driven by over 500 ADCs in clinical trials. Key players include Enhertu, Kadcyla, and Padcev, with significant sales in breast and lung cancers. The US and China lead the market, supported by robust R&D and regulatory environments.

The Cancer Antibody Drug Conjugates Market report highlights the transformative potential of ADCs in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is projected to surpass $50B by 2030, driven by ongoing clinical trials and increased R&D efforts. Key players include Padcev, Kadcyla, and Enhertu, with significant development activity in lung and breast cancer. The market is led by the US and China, with major pharmaceutical companies driving innovation.